|
AD-214 clinical trial approval
|
29 June 2023 at 8:45am
|
|
Change in substantial holding
|
31 May 2023 at 2:00pm
|
|
Change in substantial holding
|
31 May 2023 at 10:00am
|
|
Change of Director's Interest Notice x 2 (TO & DF)
|
31 May 2023 at 8:45am
|
|
Top 20 Option Holders & Distribution Schedule
|
29 May 2023 at 11:30am
|
|
Application for quotation of securities - 1AD
|
29 May 2023 at 11:30am
|
|
Investor Summit live and recorded presentation
|
29 May 2023 at 8:45am
|
|
Investor presentation
|
25 May 2023 at 8:50am
|
|
Rights Offer results
|
25 May 2023 at 8:45am
|
|
Notice of change of exercise price of options
|
22 May 2023 at 8:55am
|
|
Despatch of Rights Offer documentation
|
8 May 2023 at 12:50pm
|
|
Investor Presentation - Rights Offer Webinar
|
3 May 2023 at 8:40am
|
|
Letter to Ineligible Foreign Shareholders
|
28 April 2023 at 10:10am
|
|
Application for quotation of securities - 1AD
|
28 April 2023 at 10:10am
|
|
Letter to Eligible Shareholders
|
28 April 2023 at 10:10am
|
|
Letter to Optionholders
|
28 April 2023 at 10:10am
|
|
Target Market Determination
|
28 April 2023 at 10:10am
|
|
Prospectus
|
28 April 2023 at 10:10am
|
|
Proposed issue of securities - 1AD
|
28 April 2023 at 10:00am
|
|
Rights Offer to fund early return to clinic and growth
|
28 April 2023 at 10:00am
|
|
Quarterly Appendix 4C and Activities Report
|
28 April 2023 at 9:40am
|
|
Notification of cessation of securities - 1AD
|
14 April 2023 at 8:45am
|
|
Notification regarding unquoted securities - 1AD
|
14 April 2023 at 8:45am
|
|
Final Director's Interest Notice
|
24 March 2023 at 10:15am
|
|
Retirement of Non-Executive Director
|
24 March 2023 at 10:15am
|
|
ShareCafe webinar presentation 3 Mar 2023
|
2 March 2023 at 8:45am
|
|
Half Yearly Report and Accounts
|
27 February 2023 at 6:20pm
|
|
Spark Plus Singapore Investor Presentation
|
24 February 2023 at 8:35am
|
|
Becoming a substantial holder
|
20 February 2023 at 9:00am
|
|
Cleansing Notice under Section 708A
|
6 February 2023 at 9:30am
|
|
Application for quotation of securities - 1AD
|
6 February 2023 at 9:10am
|
|
Application for quotation of securities - 1AD
|
6 February 2023 at 9:10am
|
|
Proposed issue of securities - 1AD
|
2 February 2023 at 2:30pm
|
|
Proposed issue of securities - 1AD
|
2 February 2023 at 2:30pm
|
|
Quarterly Appendix 4C and Activities Report
|
30 January 2023 at 9:30am
|
|
Change in substantial holding
|
25 January 2023 at 3:10pm
|
|
Publication highlights I-body potential in osteoporosis
|
25 January 2023 at 9:35am
|
|
Change of Director's Interest Notice x 2
|
24 January 2023 at 7:35pm
|
|
AdAlta welcomes new substantial shareholders
|
24 January 2023 at 9:45am
|
|
Ceasing to be a substantial holder
|
24 January 2023 at 9:35am
|
|
Second Japan patent for AD-214
|
10 January 2023 at 8:45am
|
|
Results of Meeting
|
22 November 2022 at 1:00pm
|
|
Chair address and CEO presentation to AGM
|
22 November 2022 at 9:35am
|
|
AD-214 progress and priorities webinar presentation
|
2 November 2022 at 8:45am
|
|
AD-214 progress and priorities
|
2 November 2022 at 8:45am
|
|
Balance of R&D Tax Incentive Refund received
|
27 October 2022 at 10:05am
|
|
Quarterly Appendix 4C and Activities Report
|
26 October 2022 at 8:45am
|
|
Letter to Shareholders, Notice of AGM & Proxy Form
|
20 October 2022 at 8:35am
|
|
1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
|
13 October 2022 at 8:40am
|
|
Notification of cessation of securities - 1AD
|
10 October 2022 at 2:15pm
|
AdAlta